MY150747A - Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer - Google Patents

Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer

Info

Publication number
MY150747A
MY150747A MYPI20094194A MY150747A MY 150747 A MY150747 A MY 150747A MY PI20094194 A MYPI20094194 A MY PI20094194A MY 150747 A MY150747 A MY 150747A
Authority
MY
Malaysia
Prior art keywords
compounds
cancer
treatment
pi3k
pyrido
Prior art date
Application number
Other languages
English (en)
Inventor
Chris A Buhr
Wang Longcheng
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MY150747A publication Critical patent/MY150747A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20094194 2007-04-11 2008-04-11 Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer MY150747A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91116007P 2007-04-11 2007-04-11

Publications (1)

Publication Number Publication Date
MY150747A true MY150747A (en) 2014-02-28

Family

ID=39642739

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20094194 MY150747A (en) 2007-04-11 2008-04-11 Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer

Country Status (25)

Country Link
US (2) US20100209340A1 (cg-RX-API-DMAC7.html)
EP (1) EP2142544B8 (cg-RX-API-DMAC7.html)
JP (1) JP2010523681A (cg-RX-API-DMAC7.html)
KR (1) KR20090130104A (cg-RX-API-DMAC7.html)
CN (1) CN101711249A (cg-RX-API-DMAC7.html)
AU (1) AU2008239596B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810175A2 (cg-RX-API-DMAC7.html)
CA (1) CA2683820A1 (cg-RX-API-DMAC7.html)
CO (1) CO6241119A2 (cg-RX-API-DMAC7.html)
CR (1) CR11098A (cg-RX-API-DMAC7.html)
DO (1) DOP2009000242A (cg-RX-API-DMAC7.html)
EA (1) EA018964B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099722A (cg-RX-API-DMAC7.html)
ES (1) ES2425068T3 (cg-RX-API-DMAC7.html)
IL (1) IL201209A0 (cg-RX-API-DMAC7.html)
MA (1) MA31336B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009010815A (cg-RX-API-DMAC7.html)
MY (1) MY150747A (cg-RX-API-DMAC7.html)
NI (1) NI200900183A (cg-RX-API-DMAC7.html)
NZ (1) NZ579945A (cg-RX-API-DMAC7.html)
SV (1) SV2009003389A (cg-RX-API-DMAC7.html)
TN (1) TN2009000389A1 (cg-RX-API-DMAC7.html)
UA (1) UA101315C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008127712A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200906648B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065703A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
NZ608667A (en) * 2005-10-07 2014-08-29 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
MY146420A (en) 2006-09-15 2012-08-15 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
DK2139484T3 (da) 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
AU2008239655B2 (en) * 2007-04-11 2013-06-20 Exelixis, Inc. Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer
TW201018685A (en) * 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR
NZ600954A (en) * 2009-12-22 2013-11-29 Isoindolinone inhibitors of phosphatidylinositol 3-kinase
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
CA2812089C (en) 2010-09-14 2020-02-18 Exelixis Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
KR20140096083A (ko) 2011-11-01 2014-08-04 엑셀리시스, 인코포레이티드 림프증식성 악성종양의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제로서 ｎ­（3­｛［（3­｛［2­클로로­5­（메톡시）페닐］아미노｝퀴녹살린­2­일）아미노］설포닐｝페닐）­2­메틸알라닌아미드

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
US20080255162A1 (en) * 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
CA2658725A1 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
MY146420A (en) * 2006-09-15 2012-08-15 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors

Also Published As

Publication number Publication date
CR11098A (es) 2010-01-27
ECSP099722A (es) 2009-12-28
UA101315C2 (ru) 2013-03-25
TN2009000389A1 (en) 2010-12-31
ZA200906648B (en) 2010-04-28
AU2008239596B2 (en) 2013-08-15
ES2425068T3 (es) 2013-10-11
NZ579945A (en) 2012-05-25
EP2142544B8 (en) 2013-07-03
NI200900183A (es) 2010-10-05
DOP2009000242A (es) 2010-04-30
BRPI0810175A2 (pt) 2014-12-30
CN101711249A (zh) 2010-05-19
KR20090130104A (ko) 2009-12-17
EA200970936A1 (ru) 2010-02-26
SV2009003389A (es) 2010-04-27
WO2008127712A1 (en) 2008-10-23
EP2142544B1 (en) 2013-05-22
AU2008239596A1 (en) 2008-10-23
EA018964B1 (ru) 2013-12-30
US20130343988A1 (en) 2013-12-26
CA2683820A1 (en) 2008-10-23
JP2010523681A (ja) 2010-07-15
MA31336B1 (fr) 2010-04-01
EP2142544A1 (en) 2010-01-13
US20100209340A1 (en) 2010-08-19
IL201209A0 (en) 2010-05-31
CO6241119A2 (es) 2011-01-20
MX2009010815A (es) 2009-10-29
HK1139941A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
IL260127B (en) mek inhibitors and methods of using them
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MX2010007746A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de diana de rapamicina de mamifero quinasa y fosfatidilinositol quinasa y su sintesis.
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
TW200606162A (en) Pyrazolopyridine derivatives
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
EP2142543B8 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2007146124A3 (en) Deuterated tadalafil derivatives
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
WO2010121675A3 (en) Thiazolyl-benzimidazoles
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
TW200745102A (en) Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof
MY150428A (en) Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same